About Cyclin-L2
Cyclin-L2 (CCNL2) is a protein
from Homo sapiens identified by UniProt accession
Q96S94, 520 residues long.
MolForge cross-references it against 0 known binders and
74 disease associations.
Target properties
| Protein name | Cyclin-L2 |
| UniProt accession | Q96S94 |
| Gene | CCNL2 |
| Organism | Homo sapiens |
| Length | 520 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (74)
Diseases linked to this target (Open Targets).
- peak expiratory flow · score 0.15
- body height · score 0.04
- Drugs affecting bone structure and mineralization use measurement · score 0.04
- osteoporosis · score 0.04
- myxedema · score 0.04
- heel bone mineral density · score 0.04
- eosinophil count · score 0.03
- inflammatory bowel disease · score 0.03
- drug use measurement · score 0.03
- Pallister-Hall syndrome · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96S94-F1 | alphafold | PREDICTED | 69.14 | — |
Amino-acid sequence (520 residues)
MAAAAAAAGA AGSAAPAAAA GAPGSGGAPS GSQGVLIGDR LYSGVLITLE NCLLPDDKLR FTPSMSSGLD TDTETDLRVV GCELIQAAGI LLRLPQVAMA TGQVLFQRFF YTKSFVKHSM EHVSMACVHL ASKIEEAPRR IRDVINVFHR LRQLRDKKKP VPLLLDQDYV NLKNQIIKAE RRVLKELGFC VHVKHPHKII VMYLQVLECE RNQHLVQTSW NYMNDSLRTD VFVRFQPESI ACACIYLAAR TLEIPLPNRP HWFLLFGATE EEIQEICLKI LQLYARKKVD LTHLEGEVEK RKHAIEEAKA QARGLLPGGT QVLDGTSGFS PAPKLVESPK EGKGSKPSPL SVKNTKRRLE GAKKAKADSP VNGLPKGRES RSRSRSREQS YSRSPSRSAS PKRRKSDSGS TSGGSKSQSR SRSRSDSPPR QAPRSAPYKG SEIRGSRKSK DCKYPQKPHK SRSRSSSRSR SRSRERADNP GKYKKKSHYY RDQRRERSRS YERTGRRYER DHPGHSRHRR
Explore Cyclin-L2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets